Heron Therapeutics Inc

NASDAQ:HRTX   3:59:59 PM EDT
17.60
-0.35 (-1.95%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.60B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16.86 Million
Adjusted EPS-$0.67
See more estimates
10-Day MA$18.55
50-Day MA$18.60
200-Day MA$16.70
See more pivots

HERON THERAPEUTICS, INC. /DE/ Stock, NASDAQ:HRTX

4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA 92121
United States of America
Phone: 6503662626
Number of Employees: 198

Description

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.